688373 2023-048 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次权益变动后，北京华盖信诚远航医疗产业投资合伙企业（有限合伙） （以下简称"信息披露义务人"）持有上海盟科药业股份有限公司（以下简称"公司" ）股份的比例由5.798061%变动为4.999997%； 本次权益变动不会导致公司控股股东、实际控制人发生变化，不会对公司 治理结构及持续经营产生影响。 公司于近日收到信息披露义务人送达的《上海盟科药业股份有限公司简式权益 变动报告书》，现将其有关权益变动情况公告如下： (一) 信息披露义务人的基本情况 | 企业名称 | 北京华盖信诚远航医疗产业投资合伙企业（有限合伙） | | --- | --- | | 统一社会信用代码 | 91110114MA01E29U2J | | 注册地址 | 北京市昌平区沙河镇能源东路1号院1号楼4层1单元401-3 | | 认缴资本 | 306,666.6666万元人民币 | | 企业类型 | 有限合伙企业 | | 经营范围 | 项目投资;投资管理;资产管理;投资咨询、企业 ...

Financial Performance - The company's revenue for Q3 2023 reached ¥26,162,143.66, representing an increase of 80.76% year-over-year[5] - The net loss attributable to shareholders for Q3 2023 was ¥119,336,002.30, with a cumulative loss of ¥244,458,619.10 for the year-to-date[5] - The basic and diluted earnings per share for Q3 2023 were both -¥0.18, with a year-to-date figure of -¥0.37[6] - The company's revenue for the year-to-date increased by 95.87% compared to the same period last year, driven by expanded sales channels and increased hospital coverage[10] - Total revenue for the first three quarters of 2023 reached ¥68,272,315.43, a significant increase of 96.0% compared to ¥34,856,252.61 in the same period of 2022[23] - The net loss for the first three quarters of 2023 was ¥244,458,619.10, compared to a net loss of ¥173,774,505.72 in the same period last year[24] - The basic and diluted earnings per share for the first three quarters of 2023 were both -¥0.37, compared to -¥0.31 in the same period of 2022[25] - The company reported a comprehensive loss of ¥233,615,904.71 for the first three quarters of 2023, compared to a comprehensive loss of ¥167,888,245.71 in the previous year[25] Research and Development - Research and development expenses totaled ¥106,851,465.54 in Q3 2023, accounting for 408.42% of revenue, an increase of 67.16 percentage points compared to the previous year[6] - The R&D investment for the year-to-date was ¥202,949,875.30, reflecting a 76.57% increase compared to the previous year[6] - Research and development expenses surged to ¥202,949,875.30, representing an increase of 76.3% from ¥114,940,211.45 in the first three quarters of 2022[23] - The company experienced a significant increase in R&D team size and clinical progress of projects, contributing to the rise in operational costs[10] Assets and Liabilities - The total assets at the end of Q3 2023 were ¥1,280,831,919.59, a decrease of 14.46% from the end of the previous year[6] - As of September 30, 2023, the total current assets amounted to RMB 1,163,559,404.99, a decrease of 15.1% from RMB 1,370,505,453.28 at the end of 2022[16] - The total assets decreased to RMB 1,280,831,919.59 from RMB 1,497,370,060.54, indicating a decline of 14.5%[18] - The total non-current assets decreased to RMB 117,272,514.60 from RMB 126,864,607.26, a decline of 7.5%[18] - The total liabilities decreased to RMB 1,280,831,919.59, down from RMB 1,497,370,060.54, reflecting a decrease of 14.5%[18] - The total liabilities as of the end of the third quarter of 2023 were ¥273,393,988.31, a slight decrease from ¥283,095,971.09 at the end of the previous year[19] - The total equity attributable to shareholders decreased to ¥1,007,437,931.28 from ¥1,214,274,089.45 year-over-year[19] Cash Flow - The company reported a cash flow from operating activities of -¥224,781,414.57 for the year-to-date[6] - The net cash flow from operating activities was -224,781,414.57, compared to -178,919,707.70 in the previous year, indicating a decline in operational cash flow[28] - The company reported a total cash outflow from operating activities of 310,838,619.02, compared to 225,979,395.42 in the previous year[28] - Total cash inflow from investment activities reached 3,002,899,520.59, significantly higher than 842,619,850.23 in the same period last year[28] - The net cash flow from investment activities was 263,135,168.83, a recovery from -581,605,693.99 in the previous year[28] - Cash inflow from financing activities totaled 60,000,000.00, down from 1,008,616,000.00 in the previous year[29] - The net cash flow from financing activities was -8,381,107.62, contrasting with a positive 962,047,986.64 in the same period last year[29] - The total cash and cash equivalents at the end of the period amounted to 179,156,080.20, compared to 298,400,960.61 at the end of the previous year[29] Shareholder Information - The company reported a significant increase in the number of shareholders, with the top 10 shareholders holding a total of 10.92% to 10.49% of shares each[15] - The company has not engaged in any financing or margin trading activities as of the report date[15] Operational Costs - Total operating costs for the first three quarters of 2023 amounted to ¥335,652,567.97, up 49.7% from ¥224,307,692.69 in the previous year[23] - Cash paid for purchasing goods and services was 213,235,007.86, up from 147,875,569.11 in the same period last year[28] - Cash paid to employees increased to 79,034,179.00 from 68,822,056.38 in the previous year[28]

近日，上海盟科药业股份有限公司（以下简称"盟科药业"或"公司"）自 主研发的抗生素新药 MRX-5，已收到澳大利亚人类研究伦理委员会（HREC）签发 的开展 I 期临床试验的伦理许可，并通过了澳大利亚药品管理局（TGA）的临床 试验备案。按照澳大利亚药品注册相关法律法规，临床试验备案后，公司即获得 开展该产品 I 期临床试验许可。 一、临床试验许可主要内容： 药品名称：MRX-5 片 英文名称：MRX-5 Tablets 剂型：片剂 证券代码：688373 证券简称：盟科药业 公告编号：2023-047 上海盟科药业股份有限公司 自愿披露关于公司 MRX-5 在澳大利亚获得开展 I 期临床试 验许可的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 未来，盟科药业将继续以抗感染领域药物管线为核心，积极向炎症治疗、癌 症等领域拓展，为临床上未被满足的需求提供新的治疗选择。 三、风险提示 MRX-5 片获得澳大利亚 HREC 签发的批准开展 I 期临床试验的伦理许可并 通过了 TGA 的临床试验备案，是公司新药研发的阶段性 ...

证券简称：盟科药业 证券代码：688373 盟科药业股份有限公司 投资者关系活动记录表 R特定对象调研 £分析师会议 投资者关系活动 £媒体采访 R业绩说明会 类别 □新闻发布会 R现场参观 £路演活动 □其他 形式 R现场 R网上 £电话会议 上交所2023年半年度制药及生物制品行业集体业绩说明会；财 通基金、远信投资、湘财基金、巨杉资产、泾溪投资、山东铁路 发展基金、Quartet Capital、奥昇投资、招银理财、南京双安 参与单位名称 资管、方正医药、福泽源基金、乾瞻资产、CPE源峰基金、东方 证券、拾芮私募基金、海通证券、肇万资产、中信保诚基金、中 海基金、中银基金、华宝基金、华泰证券、国新证券、国海证 券、天风证券 时间 2023年9月 地点 上海市浦东新区爱迪生路53号 上市公司接待人 公司管理层 员姓名 投资者关系活动 1. 上半年公司营收情况？ ...

FANGDA PARTNERS 上海 Shanghai·北京 Beijing·深圳 Shenzhen·广州 Guangzhou·香港 Hong Kong http://www.fangdalaw.com | 中国上海市石门一路 288 号 | | --- | | 兴业太古汇香港兴业中心二座 24 楼 | | 邮政编码:200041 | | 中国上海市石门一路 288 号 | 电子邮件 E-mail: email@fangdalaw.com | | | | --- | --- | --- | --- | | 兴业太古汇香港兴业中心二座 24 楼 | 电 话 | Tel.: | 86-21-2208-1166 | | 邮政编码：200041 | 传 真 | Fax: | 86-21-5298-5599 | 24/F, HKRI Centre Two HKRI Taikoo Hui 288 Shi Men Yi Road Shanghai 200041, PRC 上海市方达律师事务所 关于上海盟科药业股份有限公司 2023 年第二次临时股东大会的法律意见书 致：上海盟科药业股份有限公司 上海市方达律师事务所（以下简 ...

证券代码：688373 证券简称：盟科药业 公告编号：2023-046 上海盟科药业股份有限公司 2023 年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2023 年 9 月 11 日 （二） 股东大会召开的地点：中国（上海）自由贸易试验区爱迪生路 53 号 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 46 | | --- | --- | | 普通股股东人数 | 46 | | 2、出席会议的股东所持有的表决权数量 | 306,165,868 | | 普通股股东所持有表决权数量 | 306,165,868 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的 | 46.7278 | | 比例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例 | 46.7278 | | （%） | ...

中国国际金融股份有限公司 关于上海盟科药业股份有限公司 2023 年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》（以下简称"《保荐办法》"）、《上海证券交 易所科创板股票上市规则》（以下简称"《上市规则》"）、《科创板上市公司持续监管办法 （试行）》等有关法律、法规的规定，中国国际金融股份有限公司（以下称"保荐机构"） 作为上海盟科药业股份有限公司（以下简称"盟科药业"或"公司"）持续督导工作的 保荐机构，负责盟科药业上市后的持续督导工作，并出具 2023 年半年度持续督导跟踪 报告，本持续督导期间为 2023 年 1 月 1 日至 2023 年 6 月 30 日。 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并 针对具体的持续督导工作制定相应的工作计 | 保荐机构已建立健全并有效执行了持续督导 | | | | 制度，并制定了相应的工作计划。 | | | 划。 | | | 2 | 根据中国证监会相关规定，在持续督导工作 | 保荐机构已与盟科药业签订《保荐协议》，该 协议明确了双方在持续督导期间的权利和义 ...

证券代码：688373 证券简称：盟科药业 公告编号：2023-045 会议召开时间：2023年9月7日（星期四）下午13:00-15:00 会议召开地点：上海证券交易所上证路演中心 （网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于9月6日 （ 星期三 ）16:00前 通 过 公 司 电话或 邮 箱 688373@micurxchina.com进行提问。公司将在说明会上对投资者普遍关 注的问题进行回答。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对2023年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 (一)会议召开时间：2023年9月7日 下午13:00-15:00 (二)会议召开地点：上证路演中心（网址：https://roadshow.sseinfo.com/） (三)会议召开方式：上证路演中心网络互动 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完 ...

Financial Performance - The company reported a cumulative loss that has been increasing due to significant investments in drug research and development, with no profit distribution planned for the reporting period [4]. - The company has not achieved profitability in the first half of 2023, primarily due to the long development cycles and high funding requirements associated with its drug development activities [4]. - There are no plans for profit distribution or capital reserve conversion during the reporting period [6]. - The net profit attributable to shareholders was -¥125,122,616.80, compared to -¥107,747,770.82 in the previous year, indicating a continued loss [24]. - The net cash flow from operating activities was -¥131,703,959.69, worsening from -¥91,725,908.62 in the same period last year [24]. - The total assets decreased by 7.91%, from ¥1,497,370,060.54 at the end of the previous year to ¥1,378,948,676.41 [24]. - The net assets attributable to shareholders decreased by 7.86%, from ¥1,214,274,089.45 to ¥1,118,779,587.47 [24]. - The company's revenue for the first half of 2023 reached ¥42,110,171.77, representing a 106.60% increase compared to ¥20,382,644.02 in the same period last year [24]. - The basic earnings per share for the first half of 2023 was -0.19 yuan, compared to -0.21 yuan in the same period last year [25]. - The weighted average return on net assets for the first half of 2023 was -10.73%, a significant improvement from -27.25% in the previous year [26]. - The total R&D expenditure for the current period was approximately 96.1 million RMB, representing a 46.61% increase compared to 65.5 million RMB in the same period last year [112]. - The proportion of R&D expenditure to operating income decreased from 321.58% to 228.21%, a reduction of 93.37 percentage points [112]. Research and Development - The company is focusing on the development of new antibiotics to combat drug-resistant bacteria, as part of its strategic initiatives [16]. - The company has initiated a Phase II clinical trial for MRX-1 in treating complex skin and soft tissue infections in children aged 6 to 17, with 12 centers planned to participate [34]. - As of the reporting period, there are 9 investigator-initiated studies ongoing to further validate the clinical efficacy of MRX-1 in various types of resistant Gram-positive bacterial infections [35]. - The company has been actively promoting MRX-1 through its own marketing team, focusing on its differentiated clinical advantages [35]. - The company aims to address the growing global challenge of antibiotic resistance through the development of innovative anti-infection drugs [32]. - The company has established a comprehensive R&D system covering all stages of new drug development, including drug discovery and clinical trials [53]. - The company has developed a technology platform for evaluating drug metabolism, enhancing its ability to design and optimize drugs based on pharmacokinetics [105]. - The company is advancing a targeted therapy platform for kidney diseases, utilizing peptide-drug conjugates that offer high tissue permeability and lower production costs [106]. - The company is focused on expanding its pipeline for infectious disease treatments, with ongoing clinical trials for multiple new drugs [120]. - The company aims to enhance its capabilities in targeted drug development by integrating talent from biopharmaceutical research [121]. Market Strategy and Expansion - The company is actively pursuing market expansion opportunities in both domestic and international markets [16]. - The company has plans for new product launches in the upcoming quarters, aiming to enhance its product portfolio [16]. - The company is exploring potential mergers and acquisitions to strengthen its market position and capabilities [16]. - The company is considering strategic acquisitions to bolster its market position, with a budget of $200 million allocated for potential mergers and acquisitions in 2023 [186]. - The company is actively expanding its academic promotion efforts and distribution network to enhance its commercialization capabilities [137]. - The company aims to parallel develop its core products in both Chinese and major international markets to maximize global commercialization rights [130]. Environmental and Social Responsibility - The company invested RMB 21.30 million in environmental protection during the reporting period [168]. - The company has established strict waste management protocols, ensuring compliance with hazardous waste regulations and reducing environmental impact [170]. - Mengke Pharmaceutical's wastewater and air emissions are managed according to relevant policies, with regular monitoring to ensure compliance [171]. - The company has implemented a strict occupational health management system, ensuring regular health check-ups for laboratory staff [175]. - The company promotes green office practices, encouraging resource-saving measures such as double-sided printing and recycling [177]. - The company adheres to various environmental protection laws and has developed internal regulations for waste disposal and employee health management [176]. Risks and Challenges - The company emphasizes the potential risks associated with its future plans and development strategies, urging investors to be aware of investment risks [7]. - The company is facing risks related to not yet being profitable, with significant investments in R&D and commercialization efforts [136]. - The company relies on a single supplier, Zhejiang Huahai, for production, which poses a risk if the supplier fails to meet production requirements [142]. - The company is currently in the early stages of commercialization, with only one product approved, leading to potential revenue limitations [141]. Shareholder and Stock Management - The company committed to not transferring or proposing to repurchase shares held prior to the public offering for 12 months post-listing and 6 months after departure [191]. - The company will implement stock repurchase plans if the stock price falls below the latest audited net asset value per share for 20 consecutive trading days within three years post-listing [192]. - The company guarantees that the funds used for stock repurchases will come from its own funds [192]. - The company will ensure compliance with relevant laws and regulations regarding share reduction [192]. - The company will not sell shares held prior to the public offering during the lock-up period [192]. - The company will publicly explain any failure to implement the stock price stabilization measures and apologize to shareholders if the conditions for such measures are met but not acted upon [194].

上海盟科药业股份有限公司独立董事 关于公司第一届董事会第二十六次会议相关议案 的独立意见 我们一致同意公司董事会将该议案提交股东大会审议。 独立董事：黄寒梅、包群、周伟澄 2023 年 8 月 25 日 （本页无正文,为《上海盟科药业股份有限公司独立董事关于公司第一届董事会 第二十六次会议相关议案的独立意见》的签字页 ) 独立董事签字: 上海盟科药业股份有限公司（以下简称"公司"）于 2023 年 8 月 25 日召开了第 一届董事会第二十六次会议。我们作为公司的独立董事，在仔细审阅了第一届董事 会第二十六次会议的相关文件后，经审慎分析，我们认为： 一、《关于<公司 2023 年半年度募集资金存放与使用情况的专项报告>的议案》的 独立意见 我们认为，公司编制的 2023 年半年度募集资金存放与使用情况的专项报告，募 集资金的审核程序符合《上市公司监管指引第 2 号——上市公司募集资金管理和使 用的监管要求》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运 作》等相关法律法规的要求。公司对募集资金进行了专户存储和专项使用，及时履 行了相关信息披露义务，募集资金具体使用情况与公司披露情况一致，不存在 ...